CA-FORESCOUT
Forescout, a global cybersecurity leader and a key provider of cybersecurity solutions to the U.S. Department of Defense (DoD), announced today that it secured a new contract with the DoD as it enters year four of the highly successful Comply-to-Connect (C2C) program. The program’s next stage will be to configure delivered capabilities to enforce zero trust access principles across the DoD Information Network (DoDIN) enterprise and bring the DoD closer to the goals set forth in the Department’s Zero Trust Strategy.
As advocated by the Defense Information System Agency (DISA) C2C Program Management Office (PMO), the new contract also delivers additional capabilities to the C2C platform that revolutionize security of Operational Technology networks and integrates risk management and decision making into the existing C2C platform. This addition further positions the DoD to apply NIST zero trust principles to millions of devices across the enterprise. Implementation of zero trust principles using Forescout’s C2C capabilities is already being accomplished in some areas of the Army, via an initiative being taught at Fort Gordon school houses and referenced in Defense Acquisition University.
With the first three steps of the program – visibility, compliance assessment, and automated remediation – well underway, administrators can now use Forescout’s orchestration capabilities to manage policy enforcement points to create the desired effects on an individual user/device/access request basis. Additionally, Forescout’s continuous monitoring capabilities are at work to ensure connected devices don’t fall out of compliance due to files getting corrupted, simple administrative mistakes, or malicious adversarial actions, all of which occur daily on the DoDIN.
C2C is one of the largest government cybersecurity initiatives in the world delivering enterprise scale capabilities for managing cyber operational risk. With the program now in its fourth year, automated control of access to and within the DoDIN will ensure that each network user has the access necessary to achieve their mission without exposing other users to threats that could impact their ability to complete their mission.
“We are proud to once again be trusted by so many organizations to secure the backbone of their operations: the networks that connect everything,” said Barry Mainz, CEO, Forescout. “Each DoDIN user should have confidence that their slice of the network is secure and ready for them to accomplish their mission. That’s what we are delivering through C2C.”
Today, the Forescout platform provides comprehensive capabilities for the DoD’s C2C security framework that enables the critical first pillar of DISA’s zero trust program called Thunderdome. This includes:
- Network-based discovery and classification of assets, including an expanding set of “unmanaged” assets that are unable to operate agents (C2C Steps 1 and 2)
- Integration with other enterprise solutions such as Identity, Credential, and Access Management (ICAM); Security Information Event Management (SIEM); and Vulnerability Assessment products to automate compliance of the cybersecurity posture and establish trust for every connecting asset (C2C Step 3)
- Orchestration of policy enforcement points across the infrastructure to enforce network access control and segmentation of assets as well as complete situational awareness of the network posture (C2C Steps 4 and 5)
“We look forward to introducing cloud-based advanced threat analysis tools into the C2C program’s portfolio of capabilities and adding further value on DoD’s zero trust journey,” added Mainz. “We’ve really just begun to unleash the power of our platform within the DoD. The best is still ahead.”
Additional Resources
- Forescout C2C Overview
- Achieving Comply-to-Connect requirements with the Forescout platform
- DoD Zero Trust Strategy
- DISA Thunderdome Presentation at AFCEA TechNet-Cyber
About Forescout
Forescout Technologies, Inc., a global cybersecurity leader, continuously identifies, protects and helps ensure the compliance of all managed and unmanaged connected cyber assets – IT, IoT, IoMT and OT. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide vendor-agnostic, automated cybersecurity at scale. The Forescout® Platform delivers comprehensive capabilities for network security, risk and exposure management, and extended detection and response. With seamless context sharing and workflow orchestration via ecosystem partners, it enables customers to more effectively manage cyber risk and mitigate threats. www.forescout.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230914036853/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
